CJC-1295 vs KPV
Side-by-side comparison of key properties, dosing, and research.
- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
- Admin Route
- SubQ
- Oral, SubQ, Topical
- Research
- —
- —
- Typical Dose
- 100 mcg
- 500 mcg – 1 mg
- Frequency
- Once daily, before bed
- Once to twice daily
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Reduces intestinal inflammation (IBD, Crohn's, colitis)
- Promotes gut mucosal healing and barrier integrity
- Accelerates wound healing topically
- Suppresses systemic inflammatory cytokines
- Antimicrobial properties against pathogens
- Reduces neuroinflammation when administered systemically
- May improve symptoms of inflammatory skin conditions
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Generally very well tolerated
- Mild injection site reactions (SC)
- Rare: transient flushing
- Stacks With
- —
- —